Novo Nordisk A/S (NYSE:NVO) Stock Holdings Boosted by Legacy Financial Advisors Inc.

Legacy Financial Advisors Inc. lifted its position in Novo Nordisk A/S (NYSE:NVO) by 13.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,025 shares of the company’s stock after buying an additional 1,393 shares during the period. Legacy Financial Advisors Inc.’s holdings in Novo Nordisk A/S were worth $1,244,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Jennison Associates LLC increased its holdings in shares of Novo Nordisk A/S by 100.3% in the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock valued at $2,129,761,000 after buying an additional 11,727,507 shares in the last quarter. Polen Capital Management LLC purchased a new stake in shares of Novo Nordisk A/S during the third quarter valued at $718,995,000. FMR LLC boosted its position in shares of Novo Nordisk A/S by 122.7% in the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after purchasing an additional 6,654,614 shares during the period. Morgan Stanley increased its stake in Novo Nordisk A/S by 96.5% in the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after purchasing an additional 4,526,199 shares in the last quarter. Finally, Loomis Sayles & Co. L P raised its holdings in Novo Nordisk A/S by 91.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after buying an additional 4,350,862 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.8 %

NYSE NVO traded down $0.97 on Friday, reaching $123.05. The stock had a trading volume of 5,932,926 shares, compared to its average volume of 3,905,318. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The business has a 50 day moving average price of $127.20 and a 200 day moving average price of $112.93. The company has a market capitalization of $552.19 billion, a price-to-earnings ratio of 42.43, a P/E/G ratio of 2.06 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a return on equity of 92.21% and a net margin of 36.56%. On average, analysts forecast that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Analyst Ratings Changes

NVO has been the subject of several recent analyst reports. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price for the company. UBS Group began coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus price target of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.